Skip to main content
. Author manuscript; available in PMC: 2018 Nov 10.
Published in final edited form as: ACS Infect Dis. 2017 Sep 27;3(11):854–865. doi: 10.1021/acsinfecdis.7b00135

Figure 2.

Figure 2

Structures of the natural product CJ-16,264 (left) and the synthetic analog KCN-AAS-35 (right). To demonstrate the effectiveness of our approach, an antibiotic with a unique structure and unknown mechanism of action was characterized. The selected antibiotic is a synthetic derivative of the natural pyrrolizidinone antibiotic CJ-16,264 (left) and is referred to as KCN-AAS-35 (right). The pyrrolizidinone structure of these compounds is not present in any other class of antibiotics and therefore indicates they likely have a unique mechanism of action. KCN-AAS-35 was selected for these studies since it has a simpler structure and was easier to synthesize.22